In a significant regulatory achievement, Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection conducted by Brazil’s health regulatory authority, ANVISA, for its API-III manufacturing facility located at Karakhadi, Gujarat.
According to the company’s regulatory filing submitted to stock exchanges on May 15, 2026, the inspection was carried out from May 11 to May 15, 2026, and concluded without any observations.